CTLA4 and neoplasm: Clone 87CAB3 demonstrated equivalent anti-tumor efficacy as the parental CTLA-4 (ipilimumab analogue, “IpA”) in syngeneic MC38 tumors implanted into human CTLA-4 knock-in mice.